An engineered (CAGA)<sub>12</sub>-EGFP cell-based biosensor for high-content and accurate detection of active TGF-

Qian Ruan,Xuezhen Lin,Lixia Wang,Niu Wang,Yu Zhao,Hao Wang,Fu-Ying Tian,Ning Hu,Ying Li,Bo Zhao
DOI: https://doi.org/10.1016/j.bios.2022.114884
2023-01-01
Abstract:Transforming growth factor-beta (TGF-beta) regulates multiple fundamental physiological processes and is closely related to severe diseases such as cancer, fibrosis, immune disorders and cardiovascular diseases. TGF-beta is thus an important biomarker for clinical diagnosis and prognosis, and a crucial target for therapeutics development. Here we describe a high-content, serum-free, easy-to-use, and cost-effective (CAGA)(12)-EGFP cell-based biosensor for accurate measurements of active TGF-beta. Together with non-destructive and continuous measurement protocol and data processing method established here, the biosensor is capable of detecting active TGF-beta 1 in the range of 0.024-6.25 ng/mL concentration with >91% accuracy and high repeatability. Overall, the engineered (CAGA)(12)-EGFP biosensor is a powerful tool for detection of active TGF-beta and for mechanistic study of the TGF-beta pathway. The greatly reduced cost and operating simplicity also makes it a highly potent in vitro platform for highthroughput screening of anti-TGF-beta therapeutics.
What problem does this paper attempt to address?